Home » Bayer’s Finerenone Delays CKD Progression in Trial
Bayer’s Finerenone Delays CKD Progression in Trial
Drugs Research and Development
Bayer said its experimental drug finerenone delayed the progression of chronic kidney disease (CKD) in patients with type 2 diabetes in a late-stage study.
The phase 3 trial enrolled 5,700 participants across 48 countries, with patients randomized to receive finerenone 10 mg or 20 mg once-a-day or a placebo, in addition to standard of care.
Patients receiving finerenone saw a delayed CKD progression as measured by time to first occurrence of kidney failure or renal death and by time to first occurrence of heart disease-related death.
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist that offsets the negative effects of overactivation of the mineralocorticoid receptor, which can damage the kidneys and heart.